Le Lézard
Classified in: Health
Subjects: PER, PET

Aratana Therapeutics' Board of Directors Appoints Craig Tooman Chief Executive Officer


LEAWOOD, Kan., Jan. 17, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, announced today the Company's Board of Directors has appointed Craig Tooman to serve as President and Chief Executive Officer of Aratana, and elected Tooman to the Board of Directors.

Aratana Therapeutics logo

"Craig is a seasoned leader with decades of executive level experience and a strong résumé of operational expertise, including in pet therapeutics and the broader pharmaceutical industry. Aratana's Board of Directors was united in the decision to appoint Craig as CEO," said Wendy Yarno, Chairperson of the Aratana Therapeutics Board of Directors. "We are confident he will provide the leadership and business strategy required to evolve the business."

Craig Tooman was the first independent member of Aratana's Board of Directors from April 2012 to November 2013. He served as Chair of the Audit Committee before transitioning to Chief Financial Officer for Aratana in November 2013. As Chair of the Audit Committee, Tooman played a vital role in successfully completing the Company's initial public offering and has since been a key member of the Company's executive leadership. Tooman has built strong business relationships and has a successful track record in executive leadership roles for several pharmaceutical companies, including as Chief Executive Officer of Avanzar Medical, Inc. and Chief Financial Officer for Enzon Pharmaceuticals and Ikaria Inc. He has also held key executive roles at ILEX Oncology, Inc. and Pharmacia Corporation.

Effective January 17, 2019, Steven St. Peter, M.D. has resigned from the role of President and Chief Executive Officer and from the Board of Directors of Aratana. Dr. St. Peter is a founder of Aratana and served as President and Chief Executive Officer of Aratana since 2012. The Board thanks him for his six years of service as CEO and wishes him the very best on his return to venture capital.

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for dogs and cats. As a pioneer in pet therapeutics, Aratana's mission is to deliver safe and effective therapeutics that elevate the standard of care in veterinary medicine. We work with companion animal veterinarians to bring new therapeutics to market that support the needs of pets and their owners. For more information, please visit www.aratana.com.

Contacts
For investor inquires:
ir@aratana.com 
(913) 353-1026

For media inquiries:
Rachel Reiff
media@aratana.com 
(913) 353-1050

 

SOURCE Aratana Therapeutics


These press releases may also interest you

at 19:05
STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY As the European distributor of Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin), Mundipharma welcomes the news that the European Medicines Agency (EMA) has...

at 19:00
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, announced that Fitch Ratings has upgraded Bio-Rad Laboratories, Inc.'s Long-Term Issuer-Default (IDR) to "BBB" from "BBB-." The upgrade reflects...

at 19:00
Dr. Parsa Mohebi, the founder of Parsa Mohebi Hair Restoration with locations in Los Angeles and Beverly Hills, recently opened his newest medical office in the city of San Francisco. The new office, staffed by Dr. Mohebi and his medical technicians,...

at 18:45
The latest edition of Crystallography Times from Rigaku Corporation has been published and is now available on the company's global website. Crystallography Times is a monthly electronic newsletter published by Rigaku focusing on single crystal X-ray...

at 18:30
CureDuchenne, the leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, announced today it has tapped Erin Frey as Senior Director of Advocacy. In this new role, Frey is charged with building relationships...

at 18:05
Senseonics Holdings, Inc. a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced the publication in...



News published on 17 january 2019 at 20:53 and distributed by: